For patients with moderate-to-severe plaque psoriasis, the fully human anti-interleukin-17A monoclonal antibody, secukinumab, is effective, according to research published online July 9 in the New England Journal of Medicine.
Individuals with hypertension and those with long-term, regular use of beta-blocker medication may be at increased risk of developing psoriasis flares, according to research published online July 2 in JAMA Dermatology.
As research continues to be done to find the most efficient treatment for patients with plaque psoriasis a study was recently published looking at how the inclusion of topical corticosteroids can benefit the care provided.
For more than 70 years methotrexate has been a popular tool in the prescription toolkit of doctors around the world. However, a recent case report by a team from the United Kingdom showed how important it is for prescribing doctors to also keep a close eye on some of the well-known adverse events associated with the medication.
Study results show that obese patients with psoriatic arthritis who were treated with tumor necrosis factor-alpha blockers who also lost at least 5 percent of their bodyweight from baseline were much more likely to achieve minimal disease activity.